Literature DB >> 2225530

Activity of glucocerebrosidase in extracts of different cell types from type 1 Gaucher disease patients.

M C Sa Miranda1, J M Aerts, R Pinto, A Fontes, L W de Lacerda, S van Weely, J Barranger, J M Tager.   

Abstract

Glucocerebrosidase activity in extracts of leukocytes, Epstein-Barr virus transformed lymphocytes and fibroblasts from Portuguese Type 1 Gaucher disease patients was studied. The residual glucocerebrosidase activity in all extracts from patients was less than 25% if measured in the presence of bile salt taurocholate. However, if measured in the absence of bile salt the residual enzyme activity in extracts from patients was cell type specific: it was severely reduced in the case of fibroblasts, mildly reduced in the case of lymphoblasts and not significantly reduced in the case of leukocytes. The glucocerebrosidase activity in extracts from all control cell types was stimulated by taurocholate. In the patients the enzyme activity in fibroblasts extracts was also stimulated but that in lymphoblasts and leukocytes was inhibited by the bile salt. The differences in glucocerebrosidase activity (in the absence of taurocholate) in extracts from different cell types from Gaucher disease patients are attributable to differences in the proportion of glucocerebrosidase present as a monomer with low activity (form I) and as a highly active aggregate (form II) that may also contain sphingolipid activator protein 2 (SAP-2). In extracts from leukocytes and lymphocytes from Type 1 Gaucher disease patients, but not in those from fibroblasts, a relatively high proportion of enzyme is present in aggregated form with near normal specific activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2225530     DOI: 10.1111/j.1399-0004.1990.tb03573.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  6 in total

1.  Participation of asparagine 370 and glutamine 235 in the catalysis by acid beta-glucosidase: the enzyme deficient in Gaucher disease.

Authors:  Benjamin Liou; Gregory A Grabowski
Journal:  Mol Genet Metab       Date:  2009-02-13       Impact factor: 4.797

Review 2.  Variable clinical presentation in lysosomal storage disorders.

Authors:  M Beck
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

3.  Role of pH in determining the cell-type-specific residual activity of glucocerebrosidase in type 1 Gaucher disease.

Authors:  S van Weely; M van den Berg; J A Barranger; M C Sa Miranda; J M Tager; J M Aerts
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

Review 4.  Laboratory and genetic evaluation of Gaucher disease.

Authors:  Olaf A Bodamer; Christina Hung
Journal:  Wien Med Wochenschr       Date:  2010-08-16

Review 5.  Alglucerase. A review of its therapeutic use in Gaucher's disease.

Authors:  R Whittington; K L Goa
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

6.  Molecular characterisation of type 1 Gaucher disease families and patients: intrafamilial heterogeneity at the clinical level.

Authors:  O Amaral; A M Fortuna; L Lacerda; R Pinto; M C Sa Miranda
Journal:  J Med Genet       Date:  1994-05       Impact factor: 6.318

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.